S2CID 260310609
2 If anything goes wrong with any of these steps, such as low stomach acid (e.g
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
This facilitates migration, proliferation, and differentiation of repair cells in the skin [53, 54]
This selective thyroid hormone receptor-beta agonist acts directly on hepatic lipid metabolism, reducing steatosis, inflammation, and, most importantly, fibrotic scarring